Reuters logo
BRIEF-Recordati acquisition of rights to Astrazeneca’s metoprolol based treatments in Europe completed
July 3, 2017 / 6:16 AM / in 3 months

BRIEF-Recordati acquisition of rights to Astrazeneca’s metoprolol based treatments in Europe completed

July 3 (Reuters) - RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA:

* AGREEMENT WITH ASTRAZENECA FOR PURCHASE OF RIGHTS TO SELOKEN/SELOKEN ZOK AND ASSOCIATED LOGIMAX FIXED DOSE COMBINATION TREATMENTS IN EUROPE IS CONCLUDED

* CONSIDERATION FOR ACQUISITION OF THE ASSETS OF $ 290 MILLION (€ 258 MILLION) WAS PAID AT THE CLOSING

* THE AGREEMENT HAS BEEN COMPLETED WITH EXCEPTION OF ROMANIA, WHICH IS SUBJECT TO SEPARATE CLOSING Source text: tmsnrt.rs/2shDqpE Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below